Watch Now
NEWEST VIDEO
Watch Now
Creating the Singularity where is neuromodulation taking us
growth becomes exponential and irreversible. He challenges the idea of hardware unification across companies and instead reframes singularity as a coming wave of revolutionary innovation. Highlighting breakthroughs in neurorestoration, brain-computer interfaces, optogenetics, and AI-driven performance enhancement, he envisions a future where neuromodulation reshapes mobility, cognition, and memory. From paralyzed patients walking again to implantable memory-enhancing technologies, Dr. Deer outlines how these advancements could transform pain management, disability care, and human potential—while cautioning about ethical implications and the “tribal” limitations of device brand loyalty.
High Frequency Stimulation Data Matters
This presentation explores the clinical value of 10 kHz high-frequency spinal cord stimulation (HF-SCS) for treating various chronic pain conditions, including non-surgical refractory back pain, diabetic peripheral neuropathy, and chronic abdominal pain. The speaker reviews pivotal studies demonstrating long-term pain relief and functional improvements, highlighting data integrity, trial design, and superior outcomes compared to traditional paresthesia-based systems. Additionally, he introduces new technologies for phantom limb pain and ultra-high-frequency peripheral stimulation. The session emphasizes the need for wider adoption of advanced waveforms, given their efficacy and reduced explant rates, particularly for underserved and complex pain populations.
Watch Now
NEWEST VIDEO
Watch Now
NEWEST VIDEO
The Closed Loop Revolution
This presentation explores the transformative impact of closed-loop spinal cord stimulation (SCS) using evoked compound action potentials (ECAPs). Unlike traditional open-loop systems, which blindly deliver constant stimulation despite anatomical or physiological changes, closed-loop technology continuously adjusts output in real time, maintaining optimal activation within a patient’s therapeutic window. Clinical trials, especially the EVOKE trial, demonstrated superior long-term outcomes, including pain relief, improved function, and reduced opioid use. The future of neuromodulation lies in expanding closed-loop applications to non-tonic waveforms like burst and high-frequency stimulation, enhancing personalization and effectiveness across diverse pain conditions.
Watch Now
Watch Now
NEWEST VIDEOS
This talk outlines the emerging field of personalized neuromodulation, with a focus on closed-loop spinal cord stimulation using evoked compound action potentials (ECAPs). Unlike traditional open-loop systems, closed-loop SCS adapts in real-time to maintain optimal spinal cord activation, leading to more consistent pain relief and patient satisfaction. The speaker presents robust data from the EVOKE trial showing long-term efficacy and introduces the concept of the dose ratio (optimal at 1.4) as a personalized biomarker. The talk advocates for a shift from pain-only outcomes to holistic metrics and positions ECAP-guided therapy as a foundational step toward individualized neuromodulation.
Watch Now
Watch Video
Toward Development of Personalized Neuromodulation Therapy
NEWEST VIDEO
Placebo Effect in Neuromodulation Therapy
This lecture explores the powerful role of the placebo effect in neuromodulation, challenging the perception that it undermines therapy efficacy. While placebo is a confounding factor in research, especially in pain trials, it can be a therapeutic asset in clinical practice. The speaker explains the neurobiology behind placebo and nocebo effects, outlines their impact on outcomes even in conditions like Parkinson's disease, and calls for ethical yet effective priming of patients to enhance treatment outcomes. Ultimately, placebo shouldn't discredit neuromodulation but should be understood, ethically managed in trials, and embraced in clinical care to maximize patient benefit.
Watch Now
Watch Now
Watch Now
growth becomes exponential and irreversible. He challenges the idea of hardware unification across companies and instead reframes singularity as a coming wave of revolutionary innovation. Highlighting breakthroughs in neurorestoration, brain-computer interfaces, optogenetics, and AI-driven performance enhancement, he envisions a future where neuromodulation reshapes mobility, cognition, and memory. From paralyzed patients walking again to implantable memory-enhancing technologies, Dr. Deer outlines how these advancements could transform pain management, disability care, and human potential—while cautioning about ethical implications and the “tribal” limitations of device brand loyalty.
Creating the Singularity where is neuromodulation taking us
Watch Now
This presentation explores the clinical value of 10 kHz high-frequency spinal cord stimulation (HF-SCS) for treating various chronic pain conditions, including non-surgical refractory back pain, diabetic peripheral neuropathy, and chronic abdominal pain. The speaker reviews pivotal studies demonstrating long-term pain relief and functional improvements, highlighting data integrity, trial design, and superior outcomes compared to traditional paresthesia-based systems. Additionally, he introduces new technologies for phantom limb pain and ultra-high-frequency peripheral stimulation. The session emphasizes the need for wider adoption of advanced waveforms, given their efficacy and reduced explant rates, particularly for underserved and complex pain populations.
High Frequency Stimulation Data Matters
Watch Now
This presentation explores the transformative impact of closed-loop spinal cord stimulation (SCS) using evoked compound action potentials (ECAPs). Unlike traditional open-loop systems, which blindly deliver constant stimulation despite anatomical or physiological changes, closed-loop technology continuously adjusts output in real time, maintaining optimal activation within a patient’s therapeutic window. Clinical trials, especially the EVOKE trial, demonstrated superior long-term outcomes, including pain relief, improved function, and reduced opioid use. The future of neuromodulation lies in expanding closed-loop applications to non-tonic waveforms like burst and high-frequency stimulation, enhancing personalization and effectiveness across diverse pain conditions.
The Closed Loop Revolution
Watch Now
Toward Development of Personalized Neuromodulation Therapy
This talk outlines the emerging field of personalized neuromodulation, with a focus on closed-loop spinal cord stimulation using evoked compound action potentials (ECAPs). Unlike traditional open-loop systems, closed-loop SCS adapts in real-time to maintain optimal spinal cord activation, leading to more consistent pain relief and patient satisfaction. The speaker presents robust data from the EVOKE trial showing long-term efficacy and introduces the concept of the dose ratio (optimal at 1.4) as a personalized biomarker. The talk advocates for a shift from pain-only outcomes to holistic metrics and positions ECAP-guided therapy as a foundational step toward individualized neuromodulation.
Watch Now
This lecture explores the powerful role of the placebo effect in neuromodulation, challenging the perception that it undermines therapy efficacy. While placebo is a confounding factor in research, especially in pain trials, it can be a therapeutic asset in clinical practice. The speaker explains the neurobiology behind placebo and nocebo effects, outlines their impact on outcomes even in conditions like Parkinson's disease, and calls for ethical yet effective priming of patients to enhance treatment outcomes. Ultimately, placebo shouldn't discredit neuromodulation but should be understood, ethically managed in trials, and embraced in clinical care to maximize patient benefit.
Placebo Effect in Neuromodulation Therapy
